NASDAQ:RTTR - Ritter Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.16 +0.06 (+2.86 %) (As of 07/22/2018 10:43 AM ET)Previous Close$2.16Today's Range$2.00 - $2.2452-Week Range$1.80 - $6.50Volume96,095 shsAverage Volume75,749 shsMarket Capitalization$10.84 millionP/E RatioN/ADividend YieldN/ABeta0.77 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California. Receive RTTR News and Ratings via Email Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:RTTR CUSIPN/A Webwww.ritterpharmaceuticals.com Phone310-203-1000 Debt Debt-to-Equity RatioN/A Current Ratio23.86 Quick Ratio23.86 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$3.03 per share Price / Book0.71 Profitability EPS (Most Recent Fiscal Year)($5.00) Net Income$-7,860,000.00 Net MarginsN/A Return on Equity-136.12% Return on Assets-85.45% Miscellaneous Employees9 Outstanding Shares5,020,000Market Cap$10.84 Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions What is Ritter Pharmaceuticals' stock symbol? Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR." When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work? Ritter Pharmaceuticals's stock reverse split before market open on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were Ritter Pharmaceuticals' earnings last quarter? Ritter Pharmaceuticals Inc (NASDAQ:RTTR) posted its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.41) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.01. View Ritter Pharmaceuticals' Earnings History. What price target have analysts set for RTTR? 4 equities research analysts have issued twelve-month target prices for Ritter Pharmaceuticals' stock. Their predictions range from $15.00 to $20.00. On average, they anticipate Ritter Pharmaceuticals' stock price to reach $16.6667 in the next twelve months. This suggests a possible upside of 671.6% from the stock's current price. View Analyst Ratings for Ritter Pharmaceuticals. What is the consensus analysts' recommendation for Ritter Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ritter Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Ritter Pharmaceuticals stock? Here are some recent quotes from research analysts about Ritter Pharmaceuticals stock: 1. According to Zacks Investment Research, "Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. " (7/18/2018) 2. HC Wainwright analysts commented, "We note that the company recorded a net loss per share of $0.41, roughly in-line with our projection of a net loss per share of $0.42. Investors should note that the prior quarterly numbers reflect pre-split calculations. Ritter conducted a 1- for-10 reverse stock split in March 2018. In the wake of these results and in anticipation of the presentation of two posters on aspects of the Phase 2b data from the previously-concluded trial of RP-628—both clinical impact and background on the patient evaluation tool used in the study—at the Digestive Disease Week (DDW) medical conference in Washington, DC at the beginning of June, we reiterate our Buy rating and 12-month price target of $15.00 per share on RTTR. RP-G28 slated to enter pivotal development near term." (5/29/2018) Who are some of Ritter Pharmaceuticals' key competitors? Some companies that are related to Ritter Pharmaceuticals include AzurRx BioPharma (AZRX), Avenue Therapeutics (ATXI), Chiasma (CHMA), Capricor Therapeutics (CAPR), Onconova Therapeutics (ONTX), Nemus Bioscience (NMUS), ProPhase Labs (PRPH), Tonix Pharmaceuticals (TNXP), PLx Pharma (PLXP), KITOV PHARMA LT/S (KTOV), SUMMIT THERAPEU/S (SMMT), Ceapro (CRPOF), NeuroVive Pharmaceutical (NEVPF), OvaScience (OVAS) and Q BioMed (QBIO). Who are Ritter Pharmaceuticals' key executives? Ritter Pharmaceuticals' management team includes the folowing people: Mr. Ira E. Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 69)Mr. Michael D. Step, CEO & Director (Age 58)Mr. Andrew J. Ritter, Co-Founder, Pres, Corp. Sec. & Director (Age 35)Mr. Jeffrey Benjamin, Principal Financial & Accounting Officer (Age 53)Mr. John W. Beck CPA, Chief Financial Officer (Age 58) When did Ritter Pharmaceuticals IPO? (RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager. Has Ritter Pharmaceuticals been receiving favorable news coverage? Media headlines about RTTR stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ritter Pharmaceuticals earned a daily sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.53 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. How do I buy shares of Ritter Pharmaceuticals? Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ritter Pharmaceuticals' stock price today? One share of RTTR stock can currently be purchased for approximately $2.16. How big of a company is Ritter Pharmaceuticals? Ritter Pharmaceuticals has a market capitalization of $10.84 million. The biotechnology company earns $-7,860,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Ritter Pharmaceuticals employs 9 workers across the globe. How can I contact Ritter Pharmaceuticals? Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected] MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 184 (Vote Outperform)Underperform Votes: 152 (Vote Underperform)Total Votes: 336MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/22/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?